What is TheraVectys?
TheraVectys is a biotechnology firm dedicated to curing cancers and preventing infectious diseases through advanced therapeutic, prophylactic, and personalized vaccination strategies. Leveraging the power of lentiviral vectors, the company aims to revolutionize global healthcare. Pre-clinical and proof-of-concept studies have demonstrated highly promising results for their vaccine candidates. A key development was the formation of a Joint-Laboratory with Institut Pasteur in June 2017 to build a robust portfolio for clinical development. TheraVectys actively collaborates with academic and industrial partners across Europe, North America, and China to advance its proprietary lentiviral vector platform. The company is poised to launch a series of clinical trials, including a Phase I/IIa assay for its Lenti-Covid nasal instillation vaccine and a proprietary Phase I/IIa clinical trial targeting cancer therapy, which is identified as its main focus. Additionally, Phase I clinical trials for hepatitis B and liver cancer candidates are being completed in partnership with Shanghai Jinwei Biotechnology in China.
How much funding has TheraVectys raised?
TheraVectys has raised a total of $51.4M across 4 funding rounds:
Private Equity
$9.4M
Unspecified
$19.9M
Grant
$2.1M
Unspecified
$20M
Private Equity (2012): $9.4M, investors not publicly disclosed
Unspecified (2013): $19.9M led by FGP Capital
Grant (2015): $2.1M supported by Bpifrance
Unspecified (2021): $20M, investors not publicly disclosed
Key Investors in TheraVectys
FGP Capital
FGP Capital is a Swiss investment firm focused on identifying and nurturing late-stage opportunities in healthcare and technology sectors, particularly through university spin-offs. The company specializes in financing clinical research and development for various medical conditions, including Alzheimer's, multiple sclerosis, and cancer. With a strong network of industry experts, FGP Capital aims to create shareholder value through strategic investments and active involvement in M&A activities. Their mission is to drive innovation and improve the world by investing in promising companies that push the boundaries of science and technology.
Bpifrance
Founded in 2012, based out of France, Bpifrance finances companies - at each stage of their development - with credit, guarantees and equity. Bpifrance supports them in their innovation projects and internationally. Bpifrance also ensures their export activity through a wide range of products. Consulting, university, networking and an acceleration program for startups, SMEs and mid-cap companies are also part of the offer for entrepreneurs.
What's next for TheraVectys?
With a significant influx of capital and a clear strategic direction, TheraVectys is set to accelerate its clinical development pipeline. The company's focus on both infectious diseases and oncology, particularly through its lentiviral vector technology, suggests a dual-pronged growth strategy. The recent major strategic investment indicates strong support for advancing its lead candidates, such as the Lenti-Covid vaccine and its cancer therapy programs, into later-stage clinical trials. Future endeavors will likely involve expanding collaborations, potentially seeking further strategic partnerships or financing rounds to support late-stage development and eventual commercialization, solidifying its position as a leader in immunotherapy and vaccination.
See full TheraVectys company page
